Free Trial
NASDAQ:BCRX

BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis

BioCryst Pharmaceuticals logo
$9.18 +0.40 (+4.49%)
As of 01:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX)

Key Stats

Today's Range
$8.90
$9.23
50-Day Range
$8.71
$11.19
52-Week Range
$6.02
$11.31
Volume
2.00 million shs
Average Volume
3.03 million shs
Market Capitalization
$1.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.70
Consensus Rating
Moderate Buy

Company Overview

BioCryst Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

BCRX MarketRank™: 

BioCryst Pharmaceuticals scored higher than 89% of companies evaluated by MarketBeat, and ranked 110th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioCryst Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    BioCryst Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BioCryst Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($0.36) to ($0.07) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioCryst Pharmaceuticals is -34.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioCryst Pharmaceuticals is -34.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    BioCryst Pharmaceuticals has a PEG Ratio of 2.50. PEG Ratios above 1 indicate that a company could be overvalued.

  • Read more about BioCryst Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    11.59% of the float of BioCryst Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    BioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in BioCryst Pharmaceuticals has recently decreased by 3.91%, indicating that investor sentiment is improving.
  • Dividend Yield

    BioCryst Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    BioCryst Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.59% of the float of BioCryst Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    BioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in BioCryst Pharmaceuticals has recently decreased by 3.91%, indicating that investor sentiment is improving.
  • News Sentiment

    BioCryst Pharmaceuticals has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for BioCryst Pharmaceuticals this week, compared to 7 articles on an average week.
  • Search Interest

    Only 6 people have searched for BCRX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • MarketBeat Follows

    Only 6 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -45% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.80% of the stock of BioCryst Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about BioCryst Pharmaceuticals' insider trading history.
Receive BCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BCRX Stock News Headlines

Banks aren’t ready for this altcoin—are you?
The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change.
Wedbush Has Bullish Estimate for BCRX Q2 Earnings
See More Headlines

BCRX Stock Analysis - Frequently Asked Questions

BioCryst Pharmaceuticals' stock was trading at $7.52 at the start of the year. Since then, BCRX stock has increased by 21.1% and is now trading at $9.1050.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its quarterly earnings results on Monday, February, 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.06. BioCryst Pharmaceuticals's revenue for the quarter was up 40.8% on a year-over-year basis.
Read the conference call transcript
.

BioCryst Pharmaceuticals' top institutional shareholders include Doliver Advisors LP (0.13%). Insiders that own company stock include Jon P Stonehouse, Yarlagadda S Babu, Helen M Thackray, Anthony Doyle, Nancy J Hutson, Steven K Galson, Alan G Levin, Amy E Mckee, Machelle Sanders, Michael L Jones and Steve Aselage.
View institutional ownership trends
.

Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioCryst Pharmaceuticals investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Pfizer (PFE) and PayPal (PYPL).

Company Calendar

Last Earnings
2/24/2025
Today
7/09/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BCRX
CIK
882796
Employees
530
Year Founded
1986

Price Target and Rating

High Price Target
$30.00
Low Price Target
$11.00
Potential Upside/Downside
+90.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
2.5
Net Income
-$88.88 million
Pretax Margin
-10.17%

Debt

Sales & Book Value

Annual Sales
$503.49 million
Price / Cash Flow
N/A
Book Value
($2.30) per share
Price / Book
-3.82

Miscellaneous

Free Float
199,206,000
Market Cap
$1.84 billion
Optionable
Optionable
Beta
1.04

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:BCRX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners